Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer - Arkenau, H; Sachdev, J; Mita, M (J Clin Oncol, 2015)
: abstract